Market Overview:
The global tyrosine hydroxylase deficiency treatment market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The market growth is attributed to the increasing prevalence of tyrosine hydroxylase deficiency, rising awareness about the disease, and technological advancements in the field of gene therapy. Based on type, the market is segmented into medication, speech therapy, and others. The medication segment dominates the global tyrosine hydroxylase deficiency treatment market owing to high adoption rates for drugs such as levodopa and carbidopa among patients with tyrosine hydroxylase deficiency. Based on application, hospitals account for a major share of the global tyrosine hydroxylase deficiency treatment market due to increased spending by healthcare institutions on innovative therapies for treating rare diseases such as tyrosine hydroxylase deficiency. Other applications include clinics, diagnostic centers, and others segments.
Product Definition:
Tyrosine hydroxylase deficiency is a rare enzyme disorder that affects the body's ability to produce the hormone dopamine. Dopamine is important for controlling movement and mood. Treatment for tyrosine hydroxylase deficiency includes taking medication to increase dopamine levels and managing symptoms with lifestyle changes.
Medication:
Medication is the process through which a doctor or a healthcare professional provides an effective course of treatment for a medical condition. In most cases, medications are used to treat diseases and disorders. Medications can be used in two ways: as drugs or therapy. Drugs are substances that have the power to change an individual's normal functioning when introduced into the human body by way of ingestion, injection, inhalation or other means.
Speech Therapy:
Speech therapy is a form of psychological treatment that helps patients communicate more effectively. It also aids in the process of learning to speak and understand the speech accurately. In addition, it also focuses on improving voice quality, articulation, fluency & rhythm as well as develops better communication skills in patients suffering from stuttering.
The most commonly used techniques are patient-controlled devices & manual stimulation therapies which help improve muscle movement.
Application Insights:
The others segment held the largest market share of more than 60% in 2017. TYH deficiency is most commonly seen in children and young adults. The global prevalence of the disease is around 5-10%. Prevalence rates are higher among males as compared to females. Around 70% of patients diagnosed with this condition are found to be male, which may lead to social isolation for affected individuals due to lack of interest shown by other people towards their well-being.
TYH deficiency can be detected through blood tests conducted by measuring serum levels of tyrosine hydroxylase (TH). These tests help detect if there is a functional deficit or not in the body's ability to use TH properly leading into improper brain development and symptoms related thereto such as hyperactivity, restlessness, anxiety disorders etc., depending upon its functioning level at that time period during life span.
Based on application type, the market has been segmented into hospitals & clinics, diagnostic centers.
Regional Analysis:
North America dominated the global tyrosine hydroxylase deficiency treatment market in 2017. This can be attributed to the presence of key players, availability of newer generation drugs, higher healthcare expenditure and awareness campaigns regarding Sotos syndrome. In addition, high prevalence of neurodegenerative disorders such as Parkinson’s disease (PD) is also expected to drive regional growth over the forecast period.
Asia Pacific is expected to witness lucrative growth during the forecast period owing to rising disposable income and improving healthcare infrastructure in emerging countries such as China and India. Moreover, an increase in R&D investment by pharmaceutical companies for discovery of novel therapies will boost regional demand for tyrH deficiency treatment products over the next eight years.
Growth Factors:
- Increasing prevalence of Tyrosine Hydroxylase Deficiency Treatment across the globe.
- Growing demand for novel and innovative therapies for the treatment of Tyrosine Hydroxylase Deficiency Treatment.
- Rising number of research and development activities focused on the development of novel therapeutics for Tyrosine Hydroxylase Deficiency Treatment.
- increasing investments by pharmaceutical companies in the field of Tyrosine Hydroxylase Deficiency Treatment research and development .
Scope Of The Report
Report Attributes
Report Details
Report Title
Tyrosine Hydroxylase Deficiency Treatment Market Research Report
By Type
Medication, Speech Therapy, Others
By Application
Hospitals, Clinics, Diagnostic Centers, Others
By Companies
Medtronic, Pfizer, Boston Scientific, GlaxoSmithKline, Eli Lilly, Abbott, Fujifilm, GE Healthcare, Siemens Healthcare, Philips Healthcare, Shimadzu, Taj Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
206
Number of Tables & Figures
145
Customization Available
Yes, the report can be customized as per your need.
Global Tyrosine Hydroxylase Deficiency Treatment Market Report Segments:
The global Tyrosine Hydroxylase Deficiency Treatment market is segmented on the basis of:
Types
Medication, Speech Therapy, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Diagnostic Centers, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Medtronic
- Pfizer
- Boston Scientific
- GlaxoSmithKline
- Eli Lilly
- Abbott
- Fujifilm
- GE Healthcare
- Siemens Healthcare
- Philips Healthcare
- Shimadzu
- Taj Pharmaceuticals
Highlights of The Tyrosine Hydroxylase Deficiency Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Medication
- Speech Therapy
- Others
- By Application:
- Hospitals
- Clinics
- Diagnostic Centers
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Tyrosine Hydroxylase Deficiency Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Tyrosine hydroxylase deficiency is a rare genetic disorder that results in the inability to make tyrosine. This can lead to problems with brain development, including intellectual disability and seizures. Treatment typically includes a combination of medications and supplements to help compensate for the lack of tyrosine.
Some of the major players in the tyrosine hydroxylase deficiency treatment market are Medtronic, Pfizer, Boston Scientific, GlaxoSmithKline, Eli Lilly, Abbott, Fujifilm, GE Healthcare, Siemens Healthcare, Philips Healthcare, Shimadzu, Taj Pharmaceuticals.
The tyrosine hydroxylase deficiency treatment market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Tyrosine Hydroxylase Deficiency Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Tyrosine Hydroxylase Deficiency Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Tyrosine Hydroxylase Deficiency Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Tyrosine Hydroxylase Deficiency Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Tyrosine Hydroxylase Deficiency Treatment Market Size & Forecast, 2018-2028
4.5.1 Tyrosine Hydroxylase Deficiency Treatment Market Size and Y-o-Y Growth
4.5.2 Tyrosine Hydroxylase Deficiency Treatment Market Absolute $ Opportunity
Chapter 5 Global Tyrosine Hydroxylase Deficiency Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Tyrosine Hydroxylase Deficiency Treatment Market Size Forecast by Type
5.2.1 Medication
5.2.2 Speech Therapy
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Tyrosine Hydroxylase Deficiency Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Tyrosine Hydroxylase Deficiency Treatment Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Diagnostic Centers
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Tyrosine Hydroxylase Deficiency Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Tyrosine Hydroxylase Deficiency Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Tyrosine Hydroxylase Deficiency Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Tyrosine Hydroxylase Deficiency Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Tyrosine Hydroxylase Deficiency Treatment Market Size Forecast by Type
9.6.1 Medication
9.6.2 Speech Therapy
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Tyrosine Hydroxylase Deficiency Treatment Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Diagnostic Centers
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Tyrosine Hydroxylase Deficiency Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Tyrosine Hydroxylase Deficiency Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Tyrosine Hydroxylase Deficiency Treatment Market Size Forecast by Type
10.6.1 Medication
10.6.2 Speech Therapy
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Tyrosine Hydroxylase Deficiency Treatment Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Diagnostic Centers
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Tyrosine Hydroxylase Deficiency Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Tyrosine Hydroxylase Deficiency Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Tyrosine Hydroxylase Deficiency Treatment Market Size Forecast by Type
11.6.1 Medication
11.6.2 Speech Therapy
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Tyrosine Hydroxylase Deficiency Treatment Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Diagnostic Centers
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Tyrosine Hydroxylase Deficiency Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Tyrosine Hydroxylase Deficiency Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Tyrosine Hydroxylase Deficiency Treatment Market Size Forecast by Type
12.6.1 Medication
12.6.2 Speech Therapy
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Tyrosine Hydroxylase Deficiency Treatment Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Diagnostic Centers
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Tyrosine Hydroxylase Deficiency Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Tyrosine Hydroxylase Deficiency Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Tyrosine Hydroxylase Deficiency Treatment Market Size Forecast by Type
13.6.1 Medication
13.6.2 Speech Therapy
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Tyrosine Hydroxylase Deficiency Treatment Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Diagnostic Centers
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Tyrosine Hydroxylase Deficiency Treatment Market: Competitive Dashboard
14.2 Global Tyrosine Hydroxylase Deficiency Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Medtronic
14.3.2 Pfizer
14.3.3 Boston Scientific
14.3.4 GlaxoSmithKline
14.3.5 Eli Lilly
14.3.6 Abbott
14.3.7 Fujifilm
14.3.8 GE Healthcare
14.3.9 Siemens Healthcare
14.3.10 Philips Healthcare
14.3.11 Shimadzu
14.3.12 Taj Pharmaceuticals
